Paul A Ellison1, Aeli P Olson2, Todd E Barnhart2, Sabrina L V Hoffman2, Sean W Reilly3, Mehran Makvandi3, Jennifer L Bartels4, Dhanabalan Murali2, Onofre T DeJesus2, Suzanne E Lapi4, Bryan Bednarz5, Robert J Nickles2, Robert H Mach3, Jonathan W Engle6. 1. Department of Medical Physics, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. Electronic address: paellison@wisc.edu. 2. Department of Medical Physics, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. 3. Department of Radiology, Division of Nuclear Medicine and Molecular Imaging, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. 4. Department of Radiology, University of Alabama at Birmingham, Birmingham, AL, USA. 5. Department of Medical Physics, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA; Department of Engineering Physics, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. 6. Department of Medical Physics, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA; Department of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Abstract
INTRODUCTION: The radioisotopes of bromine are uniquely suitable radiolabels for small molecule theranostic radiopharmaceuticals but are of limited availability due to production challenges. Significantly improved methods were developed for the production and radiochemical isolation of clinical quality 76Br, 77Br, and 80mBr. The radiochemical quality of the radiobromine produced using these methods was tested through the synthesis of a novel 77Br-labeled inhibitor of poly (ADP-ribose) polymerase-1 (PARP-1), a DNA damage response protein. METHODS: 76Br, 77Br, and 80mBr were produced in high radionuclidic purity via the proton irradiation of novel isotopically-enriched Co76Se, Co77Se, and Co80Se intermetallic targets, respectively. Radiobromine was isolated through thermal chromatographic distillation in a vertical furnace assembly. The 77Br-labeled PARP inhibitor was synthesized via copper-mediated aryl boronic ester radiobromination. RESULTS: Cyclotron production yields were 103 ± 10 MBq∙μA-1∙h-1 for 76Br, 88 ± 10 MBq∙μA-1∙h-1 for 80mBr at 16 MeV and 17 ± 1 MBq∙μA-1∙h-1 for 77Br at 13 MeV. Radiobromide isolation yields were 76 ± 11% in a small volume of aqueous solution. The synthesized 77Br-labeled PARP-1 inhibitor had a measured apparent molar activity up to 700 GBq/μmol at end of synthesis. CONCLUSIONS: A novel selenium alloy target enabled clinical-scale production of 76Br, 77Br, and 80mBr with high apparent molar activities, which was used to for the production of a new 77Br-labeled inhibitor of PARP-1. ADVANCES IN KNOWLEDGE: New methods for the cyclotron production and isolation of radiobromine improved the production capacity of 77Br by a factor of three and 76Br by a factor of six compared with previous methods. IMPLICATIONS FOR PATIENT CARE: Preclinical translational research of 77Br-based Auger electron radiotherapeutics, such as those targeting PARP-1, will require the production of GBq-scale 77Br, which necessitates next-generation, high-yielding, isotopically-enriched cyclotron targets, such as the novel intermetallic Co77Se.
INTRODUCTION: The radioisotopes of bromine are uniquely suitable radiolabels for small molecule theranostic radiopharmaceuticals but are of limited availability due to production challenges. Significantly improved methods were developed for the production and radiochemical isolation of clinical quality 76Br, 77Br, and 80mBr. The radiochemical quality of the radiobromine produced using these methods was tested through the synthesis of a novel 77Br-labeled inhibitor of poly (ADP-ribose) polymerase-1 (PARP-1), a DNA damage response protein. METHODS: 76Br, 77Br, and 80mBr were produced in high radionuclidic purity via the proton irradiation of novel isotopically-enriched Co76Se, Co77Se, and Co80Se intermetallic targets, respectively. Radiobromine was isolated through thermal chromatographic distillation in a vertical furnace assembly. The 77Br-labeled PARP inhibitor was synthesized via copper-mediated aryl boronic ester radiobromination. RESULTS: Cyclotron production yields were 103 ± 10 MBq∙μA-1∙h-1 for 76Br, 88 ± 10 MBq∙μA-1∙h-1 for 80mBr at 16 MeV and 17 ± 1 MBq∙μA-1∙h-1 for 77Br at 13 MeV. Radiobromide isolation yields were 76 ± 11% in a small volume of aqueous solution. The synthesized 77Br-labeled PARP-1 inhibitor had a measured apparent molar activity up to 700 GBq/μmol at end of synthesis. CONCLUSIONS: A novel selenium alloy target enabled clinical-scale production of 76Br, 77Br, and 80mBr with high apparent molar activities, which was used to for the production of a new 77Br-labeled inhibitor of PARP-1. ADVANCES IN KNOWLEDGE: New methods for the cyclotron production and isolation of radiobromine improved the production capacity of 77Br by a factor of three and 76Br by a factor of six compared with previous methods. IMPLICATIONS FOR PATIENT CARE: Preclinical translational research of 77Br-based Auger electron radiotherapeutics, such as those targeting PARP-1, will require the production of GBq-scale 77Br, which necessitates next-generation, high-yielding, isotopically-enriched cyclotron targets, such as the novel intermetallic Co77Se.
Authors: Dong Zhou; Haibing Zhou; Carl C Jenks; Jason S Lewis; John A Katzenellenbogen; Michael J Welch Journal: Bioconjug Chem Date: 2009-04 Impact factor: 4.774
Authors: J A Katzenellenbogen; K D McElvany; S G Senderoff; K E Carlson; S W Landvatter; M J Welch Journal: J Nucl Med Date: 1982-05 Impact factor: 10.057
Authors: Andrew V Mossine; Allen F Brooks; Katarina J Makaravage; Jason M Miller; Naoko Ichiishi; Melanie S Sanford; Peter J H Scott Journal: Org Lett Date: 2015-11-14 Impact factor: 6.005
Authors: Aladdin Riad; Sarah B Gitto; Hwan Lee; Harrison D Winters; Paul M Martorano; Chia-Ju Hsieh; Kuiying Xu; Dalia K Omran; Daniel J Powell; Robert H Mach; Mehran Makvandi Journal: Molecules Date: 2020-12-19 Impact factor: 4.411
Authors: Dong Zhou; Huaping Chen; Cedric Mpoy; Sadia Afrin; Buck E Rogers; Joel R Garbow; John A Katzenellenbogen; Jinbin Xu Journal: Biomedicines Date: 2021-05-18